Vasopressin has two major biological actions important for blood pressure regulation: vasoconstriction (pressor) and antidiuresis (volume) (Fig. 1). Vasopressin shares these dual physiological effects with angiotensin, a potent vasoactive hormone, long known to be important in blood pressure homeostasis. However, vasopressin’s role in blood pressure regulation has been neglected and its pressor activity regarded as a pharmacological effect rather than of any physiological relevance. Recent studies, summarized in reviews [1, 2], have suggested that vasopressin may be physiologically important in the control of blood pressure and may be part of an integrated hormonal system involving the renin angiotensin-aldosterone system (RAS), the sympathetic nervous system, and catecholamines. The sum of the vasoconstrictor activity of these vasoactive hormones may determine the level of blood pressure in states such as orthostasis, salt and volume depletion, hemorrhage, and some forms of hypertension.
- Malignant Hypertension
- Fibrinoid Necrosis
- Renal Hypertension
- Plasma Vasopressin
- Blood Pressure Homeostasis
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, access via your institution.
Tax calculation will be finalised at checkout
Purchases are for personal use onlyLearn about institutional subscriptions
Unable to display preview. Download preview PDF.
Möhring J, Arbogast R, Dusing R, et al.: Vasopressor role of vasopressin in hypertension, in: (editors): Brain and Pituitary Peptides. Ferring Symposium, Munich 1979, Basel, Karger, 1980, pp 157–167.
Johnston CI, Newman M, Woods RL: Role of vasopressin in cardiovascular homeostasis and hypertension. Clin Sci 61:129s–139s, 1981.
Dousa TP: Cyclic nucleotides in the cellular action of neurohypophyseal hormones. Fed Proc 36:1867–1871, 1977.
Altura BM, Altura BT: Vascular smooth muscle and neurohypophyseal hormones. Fed Proc 36:1853–1860, 1977.
Robertson GL: The regulation of vasopressin function in health and disease. Recent Prog Horm Res 33:333–385, 1977.
Pullan PT, Johnston CI, Anderson WP, et al.: The role of vasopressin in blood pressure control and in experimental hypertension. Clin Sci Mol Med 55:251s–254s, 1978.
Cowley AW Jr, Monos E, Guyton AC: Interaction of vasopressin and the baroreceptor reflex system in the regulation of arterial blood pressure in the dog. Circ Res 34:505–514, 1974.
Pullan PT, Johnston CI, Anderson WP, et al.: Plasma vasopressin in blood pressure homeostasis and in experimental renal hypertension. Am J Physiol 239:H81–H87, 1980.
Montani J-P, Liard J-F, Schoun J, et al.: Hemodynamic effects of exogenous and endogenous vasopressin at low plasma concentrations in conscious dogs. Circ Res 47:346–355, 1981.
Vander AJ: Inhibition of renin release in the dog by vasopressin and vasotocin. Circ Res 23:605–609, 1968.
Thurston H, Laragh JH: Prior receptor occupancy as a determinant of the pressor activity of infused angiotensin in the rat. Circ Res 36:113–117, 1975.
Catt KJ, Harwood JP, Austera GI, et al.: Hormonal regulation of peptide receptors and target cell responses. Nature 280:109–116, 1979.
Aisenbrey G, Manning M, Schrier R: Specific inhibitor of the vascular effect of exogenous and endogenous arginine vasopressin (AVP). Kidney Int 19:229, 1981.
Andrews CE Jr, Brenner BM: Relative contributions of arginine vasopressin and angiotensin II to maintenance of systemic arterial pressure in the anaesthetised water-deprived rat. Circ Res 48:254–258, 1981.
McNeill JR, Wilcox WC, Pang CCY: Vasopressin and angiotensin: Reciprocal mechanisms controlling mesenteric conductance. Am J Physiol 232(3):262–266, 1976.
Cowley AW Jr, Switzer SJ, Guinn MM: Evidence and quantification of the vasopressin arterial pressure control system in the dog. Circ Res 46:58–66, 1980.
Laycock JF, Penn W, Shirley DG, et al.: The role of vasopressin in blood pressure regulation immediately following acute hemorrhage in the rat. J Physiol 292:267–275, 1979.
Möhring J, Möhring B, Petri M, et al.: Vasopressin and malignant deoxycorticosterone hypertension in rats. Clin Sci Mol Med 51:45s–48s, 1976.
Crofton JT, Share L, Shade RE, et al.: Vasopressin in the rat with spontaneous hypertension. Am J Physiol 135:H361–H365, 1978.
Möhring J, Möhring B, Petri M, et al.: Plasma vasopressin concentrations and effects of vasopressin antiserum on blood pressure in rats with malignant two-kidney Goldblatt hypertension. Circ Res 42:17–22, 1978.
Johnston CI, Pullan PT, Walter NMA: Vasoactive peptides in experimental renal hypertension. Klin Wochenschr 56 (suppl 1):81–85, 1978.
Möhring J, Möhring B, Petri M, et al.: Is vasopressin involved in the pathogenesis of malignant deoxycorticosterone hypertension in rats? Lancet 2:170–173, 1976.
Woods RL, Johnston CI: The role of vasopressin in hypertension: Studies using the Brattleboro rat. Am J Physiol 242(6):F727–F732, 1982.
Johnston CI, Abrahams JM, Woods RL: Renal hypertension in the Brattleboro diabetes insipidus rat. Ann NY Acad Sci, in press.
Woods RL, Johnston CI: Importance of antidiuretic properties of vasopressin in experimental renal hypertension. Clin Exp Pharmacol Physiol 8:519–523, 1981.
Möhring J: The case for humoral factors as well as pressure. Clin Sci Mol Med 52:111–117, 1977.
Woods RL, Abrahams JM, Kincaid-Smith P, et al.: Vascular lesions and angiotensin in malignant hypertension in the absence of vasopressin. Clin Exp Pharmacol Physiol 9:297–301, 1982.
Editors and Affiliations
© 1984 Martinus Nijhoff Publishers, Boston
About this chapter
Cite this chapter
Johnston, C.I., Imai, Y., Woods, R.L. (1984). Regulation of Blood Pressure by Vasopressin. In: Villarreal, H., Sambhi, M.P. (eds) Topics in Pathophysiology of Hypertension. Developments in Cardiovascular Medicine, vol 30. Springer, Dordrecht. https://doi.org/10.1007/978-94-009-6741-0_42
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-009-6743-4
Online ISBN: 978-94-009-6741-0
eBook Packages: Springer Book Archive